Current randomized controlled trials were included in this meta-analysis.
Teriflunomide significantly reduces annualized relapse rates of multiple sclerosis.
Teriflunomide also reduces disability progression of multiple sclerosis.
Teriflunomide has a similar safety and tolerability profile to placebo.